Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?

MeSH terms

• Aged
• Antibodies, Monoclonal / economics*
• Antibodies, Monoclonal / therapeutic use
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents / economics*
• Antineoplastic Agents / therapeutic use
• Breast Neoplasms / diagnosis
• Breast Neoplasms / drug therapy*
• Breast Neoplasms / economics
• Breast Neoplasms / mortality*
• Chemotherapy, Adjuvant / economics
• Cost of Illness*
• Cost-Benefit Analysis
• Drug Costs
• Humans
• Male
• Middle Aged
• Prognosis
• Survival Analysis
• Trastuzumab
• United States